Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 77 FCF Yield % is 2.61 as of Jul. 21, 2026, which is 60% below its 10-year median of 6.49. GuruFocus rates ROCO:3118 with a GF Score™ of 77/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Level Biotechnology ranks better than 89.92% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Level Biotechnology FCF Yield % Related Terms
Level Biotechnology FCF Yield % Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Level Biotechnology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a FCF Yield % of 2.61 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Level Biotechnology and its competitors. This is 60% below median its historical median of 6.49. According to the industry distribution chart, Level Biotechnology ranks #142 out of 1409 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Level Biotechnology's FCF Yield % too high?
Level Biotechnology's current FCF Yield % of 2.61 is 60% below median its 10-year median of 6.49. Based on the distribution chart, Level Biotechnology ranks #142 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #142 out of 1409 companies for FCF Yield %. This places Level Biotechnology in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current FCF Yield % is 2.61, which is 60% below median its own 10-year median of 6.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current FCF Yield % is 2.61, which is 60% below median its 10-year median of 6.49. Level Biotechnology's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current FCF Yield % is 2.61 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
FCF Yield %: 2.61 (60% below median its 10-year median of 6.49)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
77GF Score
Get the complete analysis for ROCO:3118
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
